Mustang Bio (NASDAQ:MBIO) Stock Price Down 4.7% – Should You Sell?
by Sarita Garza · The Markets DailyMustang Bio, Inc. (NASDAQ:MBIO – Get Free Report)’s share price was down 4.7% on Tuesday . The stock traded as low as $0.6701 and last traded at $0.7034. 76,675 shares were traded during mid-day trading, a decline of 76% from the average session volume of 322,294 shares. The stock had previously closed at $0.7381.
Wall Street Analysts Forecast Growth
Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Mustang Bio in a research report on Tuesday, April 21st. One research analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the company presently has an average rating of “Sell”.
Get Our Latest Stock Analysis on Mustang Bio
Mustang Bio Trading Down 10.6%
The company has a market cap of $4.93 million, a PE ratio of -1.35 and a beta of 2.08. The business has a fifty day moving average of $0.71 and a 200-day moving average of $0.88.
Mustang Bio (NASDAQ:MBIO – Get Free Report) last released its quarterly earnings results on Tuesday, May 5th. The company reported ($0.14) EPS for the quarter, beating analysts’ consensus estimates of ($140.00) by $139.86.
Hedge Funds Weigh In On Mustang Bio
An institutional investor recently raised its position in Mustang Bio stock. Kestra Advisory Services LLC boosted its stake in Mustang Bio, Inc. (NASDAQ:MBIO – Free Report) by 68.0% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 111,042 shares of the company’s stock after acquiring an additional 44,934 shares during the period. Kestra Advisory Services LLC owned 1.52% of Mustang Bio worth $109,000 at the end of the most recent reporting period. 9.95% of the stock is currently owned by institutional investors and hedge funds.
About Mustang Bio
Mustang Bio, Inc is a clinical‐stage biopharmaceutical company focused on the development and commercialization of novel cell and gene therapies for oncology and rare genetic diseases. The company’s primary platform leverages chimeric antigen receptor T‐cell (CAR-T) technology to target both hematologic and solid tumor indications. In parallel, Mustang Bio is advancing a portfolio of lentiviral‐based gene therapy candidates designed to address inherited metabolic disorders with high unmet medical need.
The company’s oncology pipeline includes programs directed at B-cell malignancies and aggressive brain tumors, with lead CAR-T candidates in clinical trials for glioblastoma multiforme and various B-cell leukemias and lymphomas.